Absolute Antibody Ltd
Absolute Antibody Ltd, rather than creating entirely new antibodies (or antibody-like molecules), takes existing antibodies (often from hybridomas) then manufactures them in a superior way and improves their usefulness by engineering.
The company achieves this through the use of proprietary vectors (pUV™), transient transfection of a high-yielding mammalian cell line (ABS293™) and a universal purification platform. In this way 100s of mgs can be produced within two weeks plus it allows Antibody Engineering eg rapid reformatting or generation of unusual formats like Fc Silent™, bi-specific antibodies, recombinant Fab and F(ab’)2 (AbFab2™) fragments.
Antibody sequencing, manufacturing and engineering services are offered to all antibody users and the ever-growing antibody catalog already includes 12 research-grade biosimilars, as well as recombinant versions of “classics” (e.g. anti-F4/80 [Cl:3A-1], anti-phosphotyrosine [PY20] and anti-c-myc [9E10]).
Dr Nicholas HutchingsCEO
Formed by former AstraZeneca colleagues, Aptus Clinical utilises their extensive expertise in drug development to partner with life science companies and academia in their quest to identify and develop valuable new medicines.
If you have a new clinical compound in development and are looking for strategic input to clinical development plans and study design or need access to flexible and cost effective clinical research professionals to support you in delivering high quality clinical development projects, please get in touch.
Mr Jonathan LewisBusiness Development Associate
Biopharma Technology Ltd
BTL is world-renowned in freeze drying. Our in-depth knowledge and
extensive experience enables us to resolve clients’ freeze drying
issues, design new formulations and optimise processes. We have
worked on over 1000 different products, from small drug molecules to
large complex biomolecules, foods, tissues, whole organisms,
advanced materials and archaeological artefacts. We continually
engage in research to investigate future applications for freeze drying
and to keep us at the cutting edge of this field. If you are moving into
this area we would welcome the opportunity to discuss your project
and explore how we can help you achieve your lyophilisation goals.
CatSci Ltd is a problem-solving chemistry CRO supporting the research, development and manufacture of materials for the life science and wider chemistry-using industries, with a strong scientific pedigree, large pharma background and track record of delivering successful projects.
We provide solutions based on our unique combination of computational, statistical, analytical, and synthetic chemistry plus our applied catalysis expertise. In particular, CatSci specialises in the custom synthesis of small molecule NCEs, APIs and advanced intermediates.
CatSci is well placed to meet the needs of discovery and early development chemistry, including new route design and assessment, reaction development, material supply from the mg scale up to 1 kg non-GMP, including the synthesis of air-, moisture- and heat-sensitive compounds.
A full list of our services can be found at www.catsci.com/services.
Better Chemistry for Better Products!
Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in all phases of oncology, hematology and a range of other therapeutic areas (respiratory, ophthalmology, dermatology, etc.), together with global sourcing and functional service provider (FSP) solutions. Chiltern’s 3.700 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.
Dr Jan de WittVice President, Medical Affairs
Ms Andrea Cotton-BerryGlobal Director, Client Services
Ms Frances MurphyClient Services Director
Mrs Ivana GaljerClient Services Director
Mr John O'BrienSenior Account Director
Ms Birgit MundExecutive Director, Business Development
Ms Blanca TrascasaAccount Manager
Mr Qaisar RafiqDirector, Business Development
Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an integrated service group focused on product development headquartered in Australia with offices in New Zealand, the UK and the USA.
CNS creates value for small-medium sized biotechnology companies by progressing early stage products through phase 1 & 2 clinical trials or the marketplace sooner.
CNS offers a unique service where it integrates BioDesk, an intelligent global product development and regulatory affairs consultancy, with our committed, highly experienced Australian/New Zealand clinical operations and biometrics team.
BioDesk’s expert consultants offer CMC/manufacturing, toxicology, clinical and regulatory affairs strategic advice and guide products efficiently through critical post-discovery development and into the clinic for the first time.
With over 15 years’ experience on more than 300 projects, CNS is one of the most experienced providers within the local market and a partner of choice for biotech companies.
CNS’s small-medium size is considered a big advantage when relating to similar sized clients, though CNS takes a global development/ regulatory approach to ensure value is strategically added at every stage of the product development life cycle.
Further information about CNS and its intelligent development services can be found at www.clinical.net.au
Custom Pharmaceuticals is a contract development and manufacturing organisation providing formulation development, contract manufacturing and packaging services to an international client base within the pharmaceutical industry for clinical and commercial solid oral dosage products. Areas of specialty are in hormones, controlled substances and extended/modified release based formulations.
FranceMed Pharma is a privately owned British company, established since 1981 and is fully integrated. Active in pioneering work in Ethical/OTC R&D, Manufacturing, Distribution, Marketing, Sales and Global out-licensing. Owns a number of worldwide patents & trademarks, protecting all its products which are new-to-the-world, game changing, unique, micro-fine topical sprays that treat high prevalent conditions in Dermatology, Paediatrics, Gynaecology and Emergency Medicine.
Fusion Antibodies Ltd
Fusion Antibodies is a high quality CRO that offers a range of royalty free, fee-for-services covering all stages of preclinical therapeutic and diagnostic mabs development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Fusion Antibodies wants to use its next generation CDRx humanization antibody technology platform to partner with companies interested in discovering high quality Mab leads against the next generation of therapeutic targets from mouse, rabbit, & rat antibodies. Also of interest are co-development opportunities for innovative therapeutic antibodies or targets. We have humanized >40 novel targets for pharma & biotech clients in Asia, Europe & USA in the past few years.
Fusion Antibodies provides contract services including the custom expression and purification of recombinant proteins for pre-clinical models, antibody sequencing, antibody engineering, antibody humanization, biosimilar development and cGMP services.
Fusion offers CHO and HEK293 cell line expression both in Transient and Stable for research and cGMP scale up.
Fusion Antibodies has the capabilities to act as a one-stop-shop providing its partners with ready-to-develop antibody lead candidates.
Fusion Antibodies is also committed to developing therapeutic antibodies and recombinant proteins to disease specific markers, primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record.
Fusion Antibodies has developed 2 novel humanized oncology drugs the first, Fsn0503 an anti-metastatic, anti-invasive & anti-angiogenic therapeutic antibody targeting Cathepsin S and the second Fsn1006h, a double targeting therapeutic antibody against AREG & HB-EGF ligands, both drug targets are in pre-clinical development and we seek to out licence to advance them to clinical trials.
Glythera Ltd is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics with 2 core programmes:- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs). PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems - PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars. PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept. Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies. We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™.